ICO review of Solve.Care (CAN): valuation, analysis, token cost | Digital Rating Agency
We will call you soon!
This project doesn't have a level of investment attractiveness
No
Rating
Medium
Quality Rate
No detailed scores
ICO
finished
Start: 31/03/2018
End: 01/05/2018

Solve.Care

About

Solve.Care allows direct interaction among consumers, insurers and service providers to improve health care access, reduce costs and streamline payments, regardless of whether it’s a patient, employer, insurer or government agency making a healthcare payment. The company is seeking to improve care outcomes through effective coordination and eliminate much of the cost of duplication, inefficiency, waste, abuse and fraud from the system.

Rate history

The DigRate has assigned Quality Rate Medium to Solve.Care project. Solve.Care is an international platform that will operate in the market of medical services. Solve.Care platform acts as a link between consumers of medical services, private and public medical institutions, insurers and brokers. According to Deloitte research, the global volume of the medical services market will grow from $ 7 trillion in 2015 to $ 8.7 trillion by 2020. 15-30% of these funds are wasted due to inefficiency of the system, excessive workload and various types of fraud. The project team conducted an analysis of the medical services market using the example of the United States, indicating all the factors that adversely affect the healthcare system and the benefits of using the Solve.Care platform. The project collected a softcap of $ 3 mn at the pre-sale stage. The founders and advisers of the project have successful experience in the field of health insurance for life and health; development, design and promotion of innovative tech products; information security and cryptography. From a tech point of view, the team looks very strong. Among the main competitors of the project are the following: Doctorlib. With the help of this platform you can remotely make an appointment with a doctor. For patients the platform is free, and doctors pay $ 117 per month. This startup has already attracted $ 28 mn; HealhEngine allows patients to schedule appointments with medical professionals online using a website or mobile app. The project attracted 26.7 million Australian dollars; Robomed unites healthcare providers and patients on the basis of a smart contract, the performance criteria of which are the metrics of the effectiveness of a particular medical service and the patient's satisfaction. The project attracted $ 15 mn. As of the date of the express review, the price of the RBM token is $ 0.0913 and has fallen from $ 0.354 since the start date of trading on the exchange); Medicalchain uses blockchain technology for the safe storage of medical records and the preservation of a single reliable information; It is also important to note the emergence of startups in the field of telemedicine, that allow you to consult a doctor remotely. Among them we can distinguish the RoboDoc system, which is a tele-device with a screen and a video chat with a doctor. Most competitors’ solutions are limited to improving only patient and doctor relations, while Solve.Care offers a complex system with interaction of all participants of the medical services market. That is its main advantage. The economic nature of CAN defines a token as a utility, that will be used for further purchases, payments in the system and it is not a security. (There is no information on the results of the Howey Test on the official website of the project.) According to whitepaper (section Important Disclosures), the CAN token will be subject to legal review and will carry all the SEC's requirements, as if it were security. In order to reduce the risk of tokens devaluation, there is limited issuance of tokens. All unsold tokens will be destroyed. The main factors for the high demand for CAN from private insurance companies, hospitals, doctors, and other stakeholders will be a variety of options for its use, including administration, coordination, and payment transactions for US government programs such as Medicare and Medicaid. 18% of the total number of issued tokens is reserved for project organizers and a Vesting schedule is provided, which is based on the gradual receipt by project managers of 20% of tokens every 6 months from the reserved amount and 100% vesting at 30 months. This is a motivating factor for the diligent performance of all work duties. Among the partners of the project there are such large companies and associations as: Ambisafe, FoxTailMarketing, Juscutum, and American Research&Policy Institute, that indicates a high degree of reliability of the project. The main risks of the project include the fact that the project does not have a prototype of the product, in contrast to its main competitors and the dynamic development of projects-competitors. Also, due to low marketing activity, there is a risk that it will not collect sufficient funding. In the long term, Solve.Care has all chances to become one of the main players in the healthcare market. The CAN price has a medium growth potential with considerable sensitivity to market environment. Pros and cons of the project, can be found in our review.
Token
Solve.Care

Downloads and links

Review
Whitepaper
Rating scores express an opinion of Digital Rating Agency and do not have any fact-finding mission or recommendations to buy, own, sell any of the assets or take any investment decisions. Digital Rating Agency does not undertake any responsibility for any consequences, interpretations, judgements, recommendations and other actions directly or indirectly related to the rating score, the rating assessments from Digital Rating Agency, any summary and conclusions contained in the rating report and rating releases, or the absence of abovementioned. The only source, depicting the real state of the rating score, is the official site www.digrate.com
Creative Commons
Disclaimer
Лицензия Creative Commons
Rating scores express an opinion of Digital Rating Agency and do not have any fact-finding mission or recommendations to buy, own, sell any assets and take any investment decisions. Digital Rating Agency does not undertake any responsibility for any consequences, interpretations, judgements, recommendations and other actions directly or indirectly related to the rating score, the rating operations conducted by Digital Rating Agency, any summary and conclusions contained in the rating report and rating releases, or the absence of abovementioned. The only source, depicting the real state of the rating score, is official site www.digrate.com